Dilip Shanghvi

Our focus is on finding a way to grow our business organically at a rate, so that we continue to be an attractive investment opportunity for shareholders. We would look at an acquisition only if we think that it can help us in terms of strengthening our long-term strategic capability.

I think it's a very good result considering the dose and the overall safety profile.

We will do whatever is required to become successful, and once we are successful, it pays for everything that we invest in.

We are now seeking a partner for future development and commercialization of MM-II in certain geographies. This change is due to the strategic reassessment of our pipeline.

I think it's a question of looking at how other companies, even very large companies, have a significant launch cost for new products. Once you study, I think this actually is a conservative number.

We will remain opportunistic, but the focus on dermatology and ophthalmology will continue.

The growth in specialty, whether looked at quarter-on-quarter, year-on-year, has come from both U.S. and ex-U.S. markets.

We have invited the agency to inspect our Halol, but when to inspect is a decision that they take.

Our focus was on generating a more profitable prescription. I think we've been able to achieve that.

We are very excited. Only issue is how fast can we bring the product to market, and what kind of clinical outcome benefit we are able to show while the product is in registration.

I think any biosimilar will go after the big fish, and not necessarily where the space that we are playing.

I think, especially in the context of the U.S., either a favorable judgment or settlement will always remain an option.